# Daunorubicin

## General description

Daunorubicin is an anthracycline antineoplastic agent that inhibits DNA and RNA synthesis. It is used in treatment protocols for acute lymphoblastic leukaemia, acute myelogenous leukaemia and acute promyelocytic leukaemia.

| | |
|---|---|
| **INN** | Daunorubicin |
| **ATC codes** | L01DB02 |
| **Medicine type** | Chemical agent |
| **EML status history** | First added in 1999 (TRS 895) for Lymphoid leukaemia, not elsewhere classified<br>Changed in 1999 (TRS 895) for Acute myeloid leukaemia with recurrent genetic abnormalities<br>Changed in 1999 (TRS 895) for Myeloid leukaemia |
| **Wikipedia** | Daunorubicin |
| **DrugBank** | Daunorubicin |

## Recommendations

**Section** Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg i vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)

**Indications**

Lymphoid leukaemia, not elsewhere classified

Myeloid leukaemia

Acute myeloid leukaemia with recurrent genetic abnormalities